Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension

Kontaraki, Joanna; Marketou, Maria; Parthenakis, Fragiskos I.; Maragkoudakis, Spyros; Zacharis, E.; Petousis, Stelios; Kochiadakis, George E.; Vardas, Panos

doi:10.1016/j.jash.2015.07.013

Cited by 41 publications

(30 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[19] Elsewhere, Ceolotto et al [20] correlations remained significant after correction for 24-hour systolic or diastolic blood pressure. [23] Whilst further validation is clearly required, these findings suggest that microRNAs (or panels of microRNAs) herald great potential to identify target-organ damage in hypertension, independent of blood pressure.…”

Section: Circulating Micrornas and Existing Mechanisms Of Blood Pressmentioning

confidence: 99%

Circulating microRNAs and hypertension—from new insights into blood pressure regulation to biomarkers of cardiovascular risk

Romaine

Charchar

Samani

et al. 2016

Current Opinion in Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Circulating Micrornas and Existing Mechanisms Of Blood Pressmentioning

confidence: 99%

Circulating microRNAs and hypertension—from new insights into blood pressure regulation to biomarkers of cardiovascular risk

Romaine

Charchar

Samani

et al. 2016

Current Opinion in Pharmacology

View full text Add to dashboard Cite

show abstract

“…The selection of miRNAs was based on their characteristics and the upregulation or downregulation observed in myocardial and vascular remodeling. We chose to study miRNAs whose expression has been proved in clinical and experimental studies to be affected by hypertension and that have been shown to possess a distinct expression profile in arterial hypertension with target organ damage …”

Section: Discussionmentioning

confidence: 99%

“…We measured baseline miRNA‐1, miRNA‐133a, miRNA‐21, miRNA‐208b, miRNA‐499, and miRNA‐26b gene expression levels in peripheral blood mononuclear cells (PBMCs), cells that are known to play a significant part in the pathophysiology of target organ damage . These miRNAs were chosen because they have been implicated in vascular and heart remodeling and have a distinct expression profile in hypertension . For the measurement of arterial stiffness, we used PWV, which is widely accepted as the “gold standard” measure for this purpose …”

mentioning

confidence: 99%

Low Levels of MicroRNA‐21 Are a Marker of Reduced Arterial Stiffness in Well‐Controlled Hypertension

Parthenakis

Marketou

Kontaraki

et al. 2016

J of Clinical Hypertension

View full text Add to dashboard Cite

3MicroRNAs (miRNAs) play a crucial role in myocardial and vascular remodeling and have emerged as potential diagnostic and prognostic biomarkers or as therapeutic targets. The authors aimed to investigate the expression profile of selected miRNAs in the peripheral blood of patients with well-controlled essential hypertension in relation to arterial stiffness. Expression levels of miRNAs miRNA-1, miRNA133a, miRNA-26b, miRNA-208b, miRNA-499, and miRNA-21 in peripheral blood mononuclear cells were quantified by real-time reverse transcription polymerase chain reaction. Carotid-femoral pulse wave velocity (cfPWV) and carotid radial pulse wave velocity (crPWV) were evaluated at baseline and after 1 year of effective antihypertensive therapy. A total of 95 patients (50 men, mean age 62AE9 years) with well-controlled essential hypertension were included in the analysis. Only miRNA-21 was independently correlated with changes in both cfPWV and crPWV, independently of blood pressure levels (r=À0.56 and r=À0.46, respectively; P<.001 for both). Low levels of miRNA-21 are strongly associated with an improvement in arterial stiffness in patients with well-controlled essential hypertension, independently of their blood pressure levels. These data highlight the significance of miRNA-21 in vascular remodeling and its role as a potential prognostic marker and future therapeutic target.

show abstract

“…25 Changes in microRNA levels in PBMCs of hypertensive patients are related to clinical parameters of the disease, including heart hypertrophy. 26,27 Analysis of the transcriptomic alterations observed in the left ventricular tissue and PBMCs of patients with heart failure revealed that the majority of the dysregulated pathways and functions were in common between the two tissues and that specific lncRNAs show similar modulation in PBMCs and heart tissue. 28 Our results, demonstrating associations of the lncRNAs MHRT, lncRNAs are involved in the regulation of cardiac remodelling via several different mechanisms, suggesting they represent potential therapeutic targets for the treatment of cardiac hypertrophy, heart failure and other cardiac disorders.…”

Section: Sion Inhibition Of Pathological Lvh Is An Attractive Therapmentioning

confidence: 99%

The long non‐coding RNAs MHRT,FENDRR and CARMEN, their expression levels in peripheral blood mononuclear cells in patients with essential hypertension and their relation to heart hypertrophy

Kontaraki

Marketou

Kochiadakis

et al. 2018

Clin Exp Pharma Physio

Self Cite

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) participate in the modulation of cardiac hypertrophy, and they represent potential therapeutic targets in cardiovascular disease. We investigated the expression profiles of selected lncRNAs in peripheral blood mononuclear cells of patients with essential hypertension in relation to left ventricular hypertrophy. We assessed the expression levels of the lncRNAs MHRT, FENDRR and CARMEN using real-time reverse transcription polymerase chain reaction. Hypertensive patients showed significantly higher MHRT, FENDRR and CARMEN expression levels compared with healthy controls. In addition, we observed significant negative correlations of MHRT (r = -0.323, P = 0.003) and FENDRR (r = -0.380, P = 0.001) and a positive correlation of CARMEN (r = 0.458, P < 0.001) expression levels with left ventricular mass index. Our data reveal that the lncRNAs MHRT, FENDRR and CARMEN show distinct expression profiles in hypertensive patients and they possibly represent candidate therapeutic targets in hypertensive heart disease.

show abstract

Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension

Cited by 41 publications

References 38 publications

Circulating microRNAs and hypertension—from new insights into blood pressure regulation to biomarkers of cardiovascular risk

Circulating microRNAs and hypertension—from new insights into blood pressure regulation to biomarkers of cardiovascular risk

Low Levels of MicroRNA‐21 Are a Marker of Reduced Arterial Stiffness in Well‐Controlled Hypertension

The long non‐coding RNAs MHRT,FENDRR and CARMEN, their expression levels in peripheral blood mononuclear cells in patients with essential hypertension and their relation to heart hypertrophy

Contact Info

Product

Resources

About